Impinj (PI) 10-Q 26 Oct 22 2022 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2022	Oct. 14, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Entity Registrant Name	IMPINJ, INC.
Entity Central Index Key	0001114995
Entity Current Reporting Status	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Incorporation, State or Country Code	DE
Entity Common Stock Shares Outstanding		25,914,998
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
Document Transition Report	false
Document Quarterly Report	true
Trading Symbol	PI
Entity Address, State or Province	WA
Entity File Number	001-37824
Entity Tax Identification Number	91-2041398
Entity Address, Address Line One	400 Fairview Avenue North
Entity Address, Address Line Two	Suite 1200
Entity Address, City or Town	Seattle
Entity Address, Postal Zip Code	98109
City Area Code	206
Local Phone Number	517-5300
Title of 12(b) Security	Common Stock, par value $0.001 per share
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 39,310	$ 123,903
Short-term investments	142,541	69,443
Accounts receivable, net	40,667	35,449
Inventory	31,925	21,958
Prepaid expenses and other current assets	5,507	5,049
Total current assets	259,950	255,802
Long-term investments	19,200	14,225
Property and equipment, net	31,121	27,500
Operating lease right-of-use assets	11,414	11,667
Other non-current assets	2,223	2,462
Goodwill	3,881	3,881
Total assets	327,789	315,537
Current liabilities:
Accounts payable	13,249	11,732
Accrued compensation and employee related benefits	7,936	6,365
Accrued and other current liabilities	6,080	2,481
Current portion of operating lease liabilities	3,460	4,143
Restructuring liabilities	102	591
Current portion of long-term debt		9,633
Current portion of deferred revenue	2,808	558
Total current liabilities	33,635	35,503
Long-term debt, net of current portion	279,846	278,661
Operating lease liabilities, net of current portion	11,790	11,934
Other long-term liabilities	113	279
Deferred revenue, net of current portion	344	236
Total liabilities	325,728	326,613
Commitments and contingencies (Note 5)
Stockholders' equity (deficit):
Preferred stock, $0.001 par value - 5,000 shares authorized, no shares issued and outstanding at September 30, 2022 and December 31, 2021
Common stock, $0.001 par value - 495,000 shares authorized, 25,876 and 24,737 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively	26	25
Additional paid-in capital	390,432	351,422
Accumulated other comprehensive loss	(1,730)	(39)
Accumulated deficit	(386,667)	(362,484)
Total stockholders' equity (deficit)	2,061	(11,076)
Total liabilities and stockholders' equity (deficit)	$ 327,789	$ 315,537

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	495,000,000	495,000,000
Common stock, shares issued	25,876,000	24,737,000
Common stock, shares outstanding	25,876,000	24,737,000

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Revenue	$ 68,270	$ 45,193	$ 181,210	$ 137,709
Cost of revenue	30,835	22,180	83,494	67,938
Gross profit	37,435	23,013	97,716	69,771
Operating expenses:
Research and development	18,766	16,789	55,124	46,480
Sales and marketing	9,326	8,736	28,239	24,577
General and administrative	11,087	9,860	33,888	27,012
Restructuring costs				1,263
Total operating expenses	39,179	35,385	117,251	99,332
Loss from operations	(1,744)	(12,372)	(19,535)	(29,561)
Other income, net	774	(2)	1,367	21
Induced conversion on 2019 Notes			(2,232)
Interest expense	(1,205)	(526)	(3,716)	(1,576)
Loss before income taxes	(2,175)	(12,896)	(24,116)	(31,116)
Income tax expense	(24)	(28)	(67)	(130)
Net loss	$ (2,199)	$ (12,924)	$ (24,183)	$ (31,246)
Net loss per share basic	$ (0.09)	$ (0.53)	$ (0.95)	$ (1.30)
Net loss per share diluted	$ (0.09)	$ (0.53)	$ (0.95)	$ (1.30)
Weighted-average shares outstanding basic	25,743	24,330	25,384	24,040
Weighted-average shares outstanding diluted	25,743	24,330	25,384	24,040

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Statement of Comprehensive Income [Abstract]
Net loss	$ (2,199)	$ (12,924)	$ (24,183)	$ (31,246)
Other comprehensive loss, net of tax:
Unrealized loss on investments	(504)	(7)	(1,691)	(6)
Total other comprehensive loss	(504)	(7)	(1,691)	(6)
Comprehensive loss	$ (2,703)	$ (12,931)	$ (25,874)	$ (31,252)

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Operating activities:
Net loss	$ (24,183)	$ (31,246)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation	4,456	3,171
Stock-based compensation	32,230	28,951
Accretion of discount or amortization of premium on investments	301	694
Amortization of debt issuance costs	1,203	283
Induced conversion expense related to convertible notes	2,232
Changes in operating assets and liabilities:
Accounts receivable	(5,218)	(2,042)
Inventory	(9,967)	17,895
Prepaid expenses and other assets	45	(758)
Accounts payable	1,107	(1,831)
Accrued compensation and employee related benefits	1,571	754
Accrued and other liabilities	1,741	1,063
Operating lease right-of-use assets	2,490	2,218
Operating lease liabilities	(3,064)	(2,772)
Restructuring liabilities	(489)	133
Deferred revenue	2,358	(6,106)
Net cash provided by operating activities	6,813	10,407
Investing activities:
Purchases of investments	(159,837)	(36,431)
Proceeds from maturities of investments	79,508	70,000
Purchases of property and equipment	(5,975)	(14,181)
Net cash provided by (used in) investing activities	(86,304)	19,388
Financing activities:
Principal payments on finance lease obligations		(2)
Proceeds from exercise of stock options and employee stock purchase plan	12,462	11,761
Net cash provided by (used in) financing activities	(5,102)	11,759
Net increase (decrease) in cash and cash equivalents	(84,593)	41,554
Cash and cash equivalents
Beginning of period	123,903	23,636
End of period	39,310	65,190
Supplemental disclosure of cashflow information:
Cash paid for interest	1,803	863
Purchases of property and equipment not yet paid	2,519	$ 2,173
2019 Notes
Financing activities:
Payment of 2019 Notes	$ (17,564)

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Total	Cumulative-effect Adjustment from Adoption of ASU 2020-06	Common Stock	Additional Paid-In-Capital	Additional Paid-In-Capital Cumulative-effect Adjustment from Adoption of ASU 2020-06	Accumulated Deficit	Accumulated Deficit Cumulative-effect Adjustment from Adoption of ASU 2020-06	Accumulated Other Comprehensive Income (loss)
Beginning balance at Dec. 31, 2020	$ 109,119	$ (29,301)	$ 23	$ 423,759	$ (32,743)	$ (314,666)	$ 3,442	$ 3
Beginning balance, shares at Dec. 31, 2020			23,350
Issuance of common stock	8,524		$ 1	8,523
Issuance of common stock, shares			702
Stock-based compensation	7,449			7,449
Net loss	(9,416)					(9,416)
Ending balance at Mar. 31, 2021	86,375		$ 24	406,988		(320,640)		3
Ending balance, shares at Mar. 31, 2021			24,052
Beginning balance at Dec. 31, 2020	109,119	$ (29,301)	$ 23	423,759	$ (32,743)	(314,666)	$ 3,442	3
Beginning balance, shares at Dec. 31, 2020			23,350
Net loss	(31,246)
Other comprehensive loss	(6)
Ending balance at Sep. 30, 2021	89,278		$ 24	431,727		(342,470)		(3)
Ending balance, shares at Sep. 30, 2021			24,409
Beginning balance at Mar. 31, 2021	86,375		$ 24	406,988		(320,640)		3
Beginning balance, shares at Mar. 31, 2021			24,052
Issuance of common stock	719			719
Issuance of common stock, shares			202
Stock-based compensation	10,582			10,582
Net loss	(8,906)					(8,906)
Other comprehensive loss	1							1
Ending balance at Jun. 30, 2021	88,771		$ 24	418,289		(329,546)		4
Ending balance, shares at Jun. 30, 2021			24,254
Issuance of common stock	2,518			2,518
Issuance of common stock, shares			155
Stock-based compensation	10,920			10,920
Net loss	(12,924)					(12,924)
Other comprehensive loss	(7)							(7)
Ending balance at Sep. 30, 2021	89,278		$ 24	431,727		(342,470)		(3)
Ending balance, shares at Sep. 30, 2021			24,409
Beginning balance at Dec. 31, 2021	(11,076)		$ 25	351,422		(362,484)		(39)
Beginning balance, shares at Dec. 31, 2021			24,737
Issuance of common stock	4,611			4,611
Issuance of common stock, shares			483
Stock-based compensation	11,314			11,314
Net loss	(10,461)					(10,461)
Other comprehensive loss	(677)							(677)
Ending balance at Mar. 31, 2022	(6,289)		$ 25	367,347		(372,945)		(716)
Ending balance, shares at Mar. 31, 2022			25,220
Beginning balance at Dec. 31, 2021	(11,076)		$ 25	351,422		(362,484)		(39)
Beginning balance, shares at Dec. 31, 2021			24,737
Net loss	(24,183)
Other comprehensive loss	(1,691)
Ending balance at Sep. 30, 2022	2,061		$ 26	390,432		(386,667)		(1,730)
Ending balance, shares at Sep. 30, 2022			25,876
Beginning balance at Mar. 31, 2022	(6,289)		$ 25	367,347		(372,945)		(716)
Beginning balance, shares at Mar. 31, 2022			25,220
Issuance of common stock	1,885		$ 1	1,884
Issuance of common stock, shares			327
Stock-based compensation	10,859			10,859
Net loss	(11,523)					(11,523)
Other comprehensive loss	(510)							(510)
Induced conversion on 2019 Notes	(5,681)			(5,681)
Ending balance at Jun. 30, 2022	(11,259)		$ 26	374,409		(384,468)		(1,226)
Ending balance, shares at Jun. 30, 2022			25,547
Issuance of common stock	5,966			5,966
Issuance of common stock, shares			329
Stock-based compensation	10,057			10,057
Net loss	(2,199)					(2,199)
Other comprehensive loss	(504)							(504)
Ending balance at Sep. 30, 2022	$ 2,061		$ 26	$ 390,432		$ (386,667)		$ (1,730)
Ending balance, shares at Sep. 30, 2022			25,876

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 1. Summary of Significant Accounting Policies Basis of Presentation The accompanying condensed consolidated financial statements include Impinj, Inc. and its wholly owned subsidiaries. We have eliminated intercompany balances and transactions in consolidation. We have prepared these condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles, or GAAP, and applicable rules and regulations of the Securities and Exchange Commission, or SEC, regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes as of and for the year ended December 31, 2021 included in Impinj, Inc.’s Annual Report on Form 10-K, which was filed with the SEC on February 14, 2022. The condensed consolidated balance sheet as of December 31, 2021, included herein, was derived from the audited consolidated financial statements of Impinj, Inc. The unaudited condensed consolidated interim financial statements, in the opinion of management, reflect all adjustments, consisting of normal recurring adjustments, necessary to state fairly our financial position, results of operations, and our cash flows for the periods presented. Interim results are not necessarily indicative of the results for a full year or for any other future period. Use of Estimates Preparing financial statements in conformity with GAAP requires us to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures as of the date of the financial statements, as well as the reported amounts of revenue and expenses during the periods presented. On an ongoing basis, we evaluate our estimates, including those related to revenue recognition, sales incentives, estimates to complete development contracts, deferred revenue, inventory excess and obsolescence, income taxes, determination of the fair value of stock awards and compensation and employee-related benefits. To the extent there are material differences between these estimates, judgments, or assumptions and actual results, our financial statements will be affected. Recently Adopted Accounting Standards In August 2020, the FASB issued guidance on debt with conversion and other options, or ASU 2020-06. This guidance eliminates the beneficial- and cash-conversion accounting models for convertible instruments and amends the derivative scope exception for contracts in an entity’s own equity. Additionally, this guidance requires the application of the “if-converted” method to calculate the impact of convertible instruments on diluted earnings per share. We adopted ASU 2020-06 on January 1, 2021 using the modified retrospective transition method and accounted for the 2019 Notes (as defined below) on a whole-instrument basis. Upon adoption , we recorded a $ 29.3 million increase to long-term debt, a $ 32.7 million decrease to additional paid-in capital and a $ 3.4 million decrease to accumulated deficit on January 1, 2021. We had no changes to net deferred tax liabilities with a decrease in deferred tax liability offset by a corresponding increase in valuation allowance upon adoption. We use the “if-converted” method to calculate the impact of convertible instruments on diluted earnings per share for the three and nine months ended September 30, 2022 and 2021, upon adoption of this guidance. The condensed consolidated financial statements as of and for the three and nine months ended September 30, 2022, and 2021, are presented under ASU 2020-06. Recently Issued Accounting Standards Not Yet Adopted Recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the SEC did not have, or are not expected to have, a material impact on our present or future consolidated financial statements.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 2. Fair Value Measurements Accounting standards define fair value as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. The standards also establish a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. There are three levels of inputs that may be used to measure fair value: • Level 1 — Quoted prices in active markets for identical assets or liabilities. • Level 2 — Assets and liabilities valued based on observable market data for similar instruments, such as quoted prices for similar assets or liabilities. • Level 3 — Unobservable inputs that are supported by little or no market activity; instruments valued based on the best available data, some of which is internally developed, and considers risk premiums that a market participant would require. We applied the following methods and assumptions in estimating our fair value measurements: Cash Equivalents — Cash equivalents consist of highly liquid investments, including money market funds with original maturities of less than three months at the acquisition date. We record the fair value measurement of these assets based on quoted market prices in active markets. Investments — Our investments comprise fixed income securities, which include U.S. government agency securities, corporate notes and bonds, commercial paper, treasury bills and asset-backed securities. The fair value measurement of these assets is based on observable market-based inputs or inputs that are derived principally from or corroborated by observable market data by correlation or other means. Long-term Debt — See Note 6 for the carrying amount and estimated fair value of the Notes. The following table presents the balances of assets measured at fair value on a recurring basis, by level within the fair value hierarchy, as of the dates presented (in thousands): September 30, 2022 December 31, 2021 Level 1 Level 2 Total Level 1 Level 2 Total Cash equivalents: Money market funds $ 27,430 $ — $ 27,430 $ 113,058 $ — $ 113,058 Total cash equivalents 27,430 — 27,430 113,058 — 113,058 Short-term investments: U.S. government agency securities — 75,681 75,681 — 4,066 4,066 Corporate notes and bonds — 35,995 35,995 — 36,966 36,966 Commercial paper — 18,291 18,291 — 16,489 16,489 Treasury bill — 4,490 4,490 — 4,490 4,490 Yankee bonds 1,918 1,918 — — — Asset-backed securities — 6,166 6,166 — 7,432 7,432 Total short-term investments — 142,541 142,541 — 69,443 69,443 Long-term investments: U.S. government agency securities — 17,346 17,346 — 14,225 14,225 Asset-backed securities — 1,854 1,854 — — — Total long-term investments — 19,200 19,200 — 14,225 14,225 Total $ 27,430 $ 161,741 $ 189,171 $ 113,058 $ 83,668 $ 196,726 We did no t have any Level 3 assets nor did we measure any liabilities at fair value as of September 30, 2022 or December 31, 2021. Short-term investments are expected to mature within 1 year from the reporting date. Long-term investments are expected to mature between 1 and 2 years from the reporting date. See Note 6 for the carrying amount and estimated fair value of the Notes. The following tables present the cost or amortized cost, gross unrealized gains, gross unrealized losses and total estimated fair value of our financial assets as of the dates presented (in thousands): September 30, 2022 Cost or Gross Gross Total Estimated Amortized Cost Unrealized Gains Unrealized Losses Fair Value Description: Money market funds $ 27,430 $ — $ — $ 27,430 U.S. government agency securities 94,276 — ( 1,249 ) 93,027 Corporate notes and bonds 36,374 — ( 379 ) 35,995 Yankee bonds 1,920 — ( 2 ) 1,918 Commercial paper 18,291 — — 18,291 Treasury bill 4,500 — ( 10 ) 4,490 Asset-backed securities 8,110 — ( 90 ) 8,020 Total $ 190,901 $ — $ ( 1,730 ) $ 189,171 December 31, 2021 Cost or Gross Gross Total Estimated Amortized Cost Unrealized Gains Unrealized Losses Fair Value Description: Money market funds $ 113,058 $ — $ — $ 113,058 U.S. government agency securities 18,314 — ( 23 ) 18,291 Corporate notes and bonds 36,975 3 ( 12 ) 36,966 Commercial paper 16,489 — — 16,489 Treasury bill 4,494 — ( 4 ) 4,490 Asset-backed securities 7,435 — ( 3 ) 7,432 Total $ 196,765 $ 3 $ ( 42 ) $ 196,726 Marketable securities in a continuous loss position for less than 12 months had an estimated fair value of $ 143.5 million and unrealized losses of $ 1.7 million as of September 30, 2022. Marketable securities in a continuous loss position for less than 12 months had an estimated fair value of $ 61.0 million and unrealized losses of $ 42,000 as of December 31, 2021. As of September 30, 2022, and December 31, 2021, there were no marketable securities in a continuous loss position for greater than 12 months. In making the determination as to whether the unrealized loss is other-than-temporary, for the periods presented, we have concluded that there is no plan to sell the securities nor is it more likely than not that we would be required to sell the securities before their anticipated recovery.

Inventory

Inventory	9 Months Ended
	Sep. 30, 2022
Inventory Disclosure [Abstract]
Inventory	N ote 3. Inventory The following table presents the detail of inventories as of the dates presented (in thousands): September 30, 2022 December 31, 2021 Raw materials $ 10,982 $ 6,305 Work-in-process 9,178 7,873 Finished goods 11,765 7,780 Total inventory $ 31,925 $ 21,958 For the three and nine months ended September 30, 2022, sales of fully reserved inventory had an immaterial impact on net gross margin. For the three and nine months ended September 30, 2021, sales of fully reserved inventory had a favorable net gross margin impact of 2.0 % and 1.4 %, respectively.

Stock-Based Awards

Stock-Based Awards	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Stock-Based Awards	Note 4. Stock-Based Awards Stock Options The following table summarizes stock option activity for the nine months ended September 30, 2022 (in thousands): Number of Outstanding at December 31, 2021 2,288 Granted — Exercised ( 426 ) Forfeited or expired ( 18 ) Outstanding at September 30, 2022 1,844 Vested and exercisable at September 30, 2022 1,517 Restricted Stock Units We grant (i) RSUs with a service condition, (ii) RSUs with performance and service conditions (“PSUs”), and (iii) RSUs with market and service conditions (“MSUs”) as further explained below. We historically paid annual bonuses to our senior executives and other bonus-eligible employees with PSUs. In fiscal year 2022, we will pay employees’ bonus half with cash and half with PSUs. The number of annual PSUs that will ultimately vest depends on us attaining financial metrics for the year as well as on an employee’s continued employment through the vesting date. The compensation committee and board of directors typically certify PSU attainment in the first quarter of each year. On April 12, 2021 and May 20, 2021, we granted a total of 83,750 MSUs to certain executives. The MSUs are eligible to vest based on our total stockholder return (“TSR”) relative to the TSR of the constituents in the S&P Semiconductor Select Industry Index over two measurement periods. Half of the MSUs are eligible to vest based on our relative TSR from January 1, 2021 through December 31, 2022, and half of the MSUs are eligible to vest based on our relative TSR from January 1, 2021 through December 31, 2023. We use a Monte Carlo simulation in estimating the fair value at grant date and recognize compensation cost over the implied service period. We estimated the aggregate grant-date fair value of these shares to be $ 6.4 million using the Monte Carlo simulation valuation method. On March 23, 2022 we granted a total of 57,000 MSUs to certain executives. The MSUs are eligible to vest based on our TSR relative to the TSR of the constituents in the S&P Semiconductor Select Industry Index over two measurement periods. Half of the MSUs are eligible to vest based on our relative TSR from January 1, 2022 through December 31, 2023, and half of the MSUs are eligible to vest based on our relative TSR from January 1, 2022 through December 31, 2024. We use a Monte Carlo simulation in estimating the fair value at grant date and recognize compensation cost over the implied service period. We estimated the aggregate grant-date fair value of these shares to be $ 4.6 million using the Monte Carlo simulation valuation method. The following table summarizes activity for RSUs, PSUs and MSUs for the nine months ended September 30, 2022 (in thousands): Number of Underlying Shares RSUs MSUs PSUs Outstanding at December 31, 2021 1,165 84 268 Granted 701 57 75 Vested ( 380 ) — ( 269 ) Forfeited ( 96 ) ( 25 ) ( 2 ) Outstanding at September 30, 2022 1,390 116 72 We recorded $ 262,000 and $ 2.2 million of stock-based compensation expense related to the MSUs for the three and nine months ended September 30, 2022. We recorded $ 716,000 and $ 1.3 million of stock-based compensation expense related to the MSUs for the three and nine months ended September 30, 2021. Stock-Based Compensation Expense The following table presents stock-based compensation expense included in our condensed consolidated statements of operations for the periods presented (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Cost of revenue $ 509 $ 506 $ 1,407 $ 1,266 Research and development expense 4,368 4,610 13,479 12,288 Sales and marketing expense 1,853 2,617 7,247 6,739 General and administrative expense 3,327 3,187 10,097 8,658 Total stock-based compensation expense $ 10,057 $ 10,920 $ 32,230 $ 28,951

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 5. Commitments and Contingencies For information on our commitments and contingencies, see Part II, Item 8 (Financial Statements and Supplementary Data, Note 11. Commitments and Contingencies) of our Annual Report on Form 10-K for the year ended December 31, 2021. There have been no material changes to our commitments and contingencies, outside of the ordinary course of our business, as previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2021, except for “Obligations with Third-Parties” and “Litigation” as discussed below. Obligations with Third Parties We have certain non-cancelable obligations, which include obligations with third-party manufacturers who manufacture our products. We are committed to purchase $ 47.1 million of inventory as of September 30, 2022. Litigation From time to time, we are subject to various legal proceedings or claims that arise in the ordinary course of business. We accrue a liability when management believes that it is both probable that a liability has been incurred and the amount of loss can be reasonably estimated. As of September 30, 2022 and December 31, 2021 , we did no t have material accrued contingency liabilities. The following is a description of our significant legal proceedings. Although we believe that resolving these claims, individually or in aggregate, will not have a material adverse impact on our financial statements, these matters are subject to inherent uncertainties. Patent Infringement Claims and Counterclaims Impinj Patent Infringement Claims Against NXP in California On June 6, 2019, we filed a patent infringement lawsuit against NXP USA, Inc., a Delaware corporation and subsidiary of NXP Semiconductors N.V., in the U.S. District Court for the Northern District of California, or the Court. The original complaint alleged that certain NXP integrated circuit products infringe 26 of our U.S. patents. At the order of the Court, we filed an amended complaint limited to eight of the original 26 patents. We subsequently elected to go forward with asserting infringement of six of those eight patents. We are seeking, among other things, past damages, including lost profits, but no less than a reasonable royalty; enhanced damages for willful infringement; and reasonable attorneys’ fees and costs for infringement of the asserted patents. We are also seeking an injunction against NXP USA making, selling, using, offering for sale or importing its UCODE 8 and UCODE 9 ICs. Defendants responded to our complaint on September 30, 2019 citing numerous defenses including denying infringement, claiming our asserted patents are invalid, and that the infringed patents were licensed on a royalty-free basis under Impinj’s commitments to GS1 EPCglobal. In February 2020, NXP filed inter partes review, or IPR, petitions with the Patent Trial and Appeal Board for the U.S. Patent and Trademark Office, or PTAB, against 12 of the originally asserted 26 patents, including the six patents asserted in the amended complaint. In August and September of 2020, the PTAB declined to institute review of four of the six patents at issue. On October 27, 2020, we filed a second amended complaint removing without prejudice the two of the six patents against which the PTAB instituted IPRs, leaving four patents in suit. On September 24, 2020, the Court lifted the stay on two of the four patents in suit, and on July 23, 2021, the Court held a claim construction hearing for those two patents. On September 3, 2021, the Court lifted the stay on the other two of the four patents in suit, and on March 4, 2022, the Court held a claim construction hearing for those two patents. The Court has issued a schedule that provides for, among other things, a trial for all four patents in suit beginning on June 5, 2023. The Court has also scheduled a summary judgment hearing on January 31, 2023, for any summary judgment motions filed by the parties. NXP Patent Infringement Claims Against Impinj in Washington On October 4, 2019, NXP USA, Inc. and NXP B.V., filed a patent infringement lawsuit against us in the U.S. District Court for the District of Delaware. The complaint alleges that certain of our products infringe eight U.S. patents owned by plaintiffs. The plaintiffs are seeking, among other things, past damages adequate to compensate them for our alleged infringement of each of the patents-in-suit, and reasonable attorneys’ fees and costs. They are also seeking an injunction against us, enjoining continuing acts of infringement of the patents-in-suit. We have denied that we are infringing any of the patents, and we have asserted that our supplier is licensed under four of them and that all eight are invalid. On September 23, 2020, the District of Delaware granted Impinj’s motion to transfer the case to the U.S. District Court for the Western District of Washington in Seattle. On December 11, 2020, we also moved to stay the case with respect to six of the eight patents in suit pending final resolution of petitions that we filed for IPR review by the PTAB. On February 12, 2021, the Court granted our motion to stay the case as to these six patents. The PTAB instituted IPRs on two of the six challenged patents, and ultimately issued final decisions rejecting all claims of those two patents but denied them on the other four . The Court subsequently removed the stay on the four against which IPRs were not instituted so six patents remain in suit, including three to which we claim a license through our supplier. We filed and on July 8, 2022, the U.S. Patent and Trademark Office instituted a reexamination of one of the remaining six patents and has issued an initial office action rejecting all claims. On March 9, 2021, we moved for summary judgment of noninfringement on the four patents to which we assert a license, including three of the remaining six patents. On July 28, 2021, the Court deferred ruling on our motion for summary judgment pending further discovery. On September 17, 2021, the Court struck all scheduled dates for the case pending reassignment to a new judge. On May 17, 2022, the case was reassigned to Judge John Chun. The Court held a hearing on our summary judgment motion, which pertains to three of the remaining six patents, on October 4, 2022, and also conducted a claim construction hearing on that date. The Court also issued a revised schedule that provides for, among other things, a trial date of April 10, 2023. On October 20, 2022, the Court granted our motion for summary judgment, leaving three patents remaining in suit. Impinj Patent Infringement Claims Against NXP in Texas On May 25, 2021, we filed a new patent infringement lawsuit against NXP USA, Inc. in the United States District Court for the Western District of Texas (Waco), asserting that NXP has infringed nine of our patents, including seven that were originally asserted in the Northern California case. We are seeking among other things, past damages, including lost profits, but no less than a reasonable royalty; enhanced damages for willful infringement; and reasonable attorney’s fees and costs for infringement of the asserted patents. We are also seeking an injunction against NXP making, selling, using, offering for sale or importing its UCODE 7, 8 and 9 endpoint ICs. On July 26, 2021, NXP USA filed an answer to our complaint and counterclaimed that we infringe nine patents, one of which NXP USA owns and eight of which NXP USA recently exclusively licensed from a third party. The Court issued a claim construction order on February 10, 2022. The Court has also ordered that that the initial trial will involve three patents from each side, with up to two additional trials if necessary. The current schedule sets, among other things, a deadline of March 21, 2023, for the parties to select the first set of patents for the initial trial, with that trial to begin on September 25, 2023. On July 11, 2022, the Court granted our motion to file an amended complaint adding NXP B.V. and NXP Semiconductors Netherlands B.V. as defendants. In addition, we filed petitions for reexamination on five of the patents NXP asserted in its counterclaim and all five were instituted by the U.S. Patent and Trademark Office. NXP Patent Infringement Claims Against Impinj in China On December 7, 2020, Impinj Radio Frequency Technology (Shanghai) Co., Ltd., or Impinj Shanghai, was served with patent infringement lawsuits filed in the Intellectual Property Court in Shanghai, China, or Shanghai Intellectual Property Court, in which NXP asserts that certain of our products infringe three Chinese patents owned by NXP, which closely correspond to three of the eight U.S. patents NXP has already asserted in U.S. District Court described above. The plaintiffs are seeking, among other things, past damages, and reasonable attorneys’ fees and costs. They are also seeking an injunction against us, enjoining continuing acts of infringement of the patents-in-suit. Impinj Shanghai objected to the jurisdiction of the Shanghai Intellectual Property Court and filed a motion to stay the proceedings. The jurisdictional challenge was rejected by the Shanghai court in March 2021; a subsequent appeal filed by Impinj Shanghai was denied before the IP Tribunal of the Supreme People’s Court in third-quarter 2021. Impinj, Inc. was formally served in July 2021, officially adding Impinj, Inc. to the suit. Impinj Shanghai also filed invalidity requests against all three Chinese patents before the China National Intellectual Property Administration, or CNIPA. In July 2021, the CNIPA issued decisions upholding the validity of the three Chinese patents. In October 2021, Impinj Shanghai filed for review of all of the CNIPA decisions by the Beijing Intellectual Property Court. T rials for all three patents, originally scheduled for May 22, 2022, were deferred by the Court and no new trial date has yet been set.

Long-term Debt

Long-term Debt	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Long-term Debt	Note 6. Long-term debt Convertible Senior Notes In December 2019, we issued $ 86.3 million aggregate principal amount of convertible promissory notes (the “2019 Notes”) due December 15, 2026 , and in November 2021, we issued $ 287.5 million aggregate principal amount of convertible promissory notes due May 15, 2027 (the “2021 Notes” and, together with the 2019 Notes, the “Notes”). The following table presents the outstanding principal amount and carrying value of the Notes as of the dates indicated (in thousands): September 30, 2022 December 31, 2021 Principal Amount Unamortized debt issuance costs Net Carrying Amount Principal Amount Unamortized debt issuance costs Net Carrying Amount 2019 Notes (1) (2) $ — $ — $ — $ 9,850 $ ( 217 ) $ 9,633 2021 Notes 287,500 ( 7,654 ) 279,846 287,500 ( 8,839 ) 278,661 Total Debt 287,500 ( 7,654 ) 279,846 297,350 ( 9,056 ) 288,294 Short-term Debt — — — 9,850 ( 217 ) 9,633 Long-term Debt $ 287,500 $ ( 7,654 ) $ 279,846 $ 287,500 $ ( 8,839 ) $ 278,661 (1) In November 2021, we completed a privately negotiated repurchase of $ 76.4 million principal amount of the 2019 Notes (“2019 Note Repurchase”) which we accounted for as an induced conversion in accordance with Accounting Standards Codification 470-20, Debt with Conversion and Other Options (ASC 470-20). As a result of this transaction, we recorded unamortized debt issuance costs of $ 1.8 million in additional paid-in capital for the year ended December 31, 2021. Please refer to section "Repurchase of the Convertible Senior Notes – 2019". 9.85 million of the remaining principal amount of the 2019 Notes (“2019 Note Repurchase”) which we accounted for as an induced conversion in accordance with Accounting Standards Codification 470-20, Debt with Conversion and Other Options (ASC 470-20). As a result of this transaction, we recorded unamortized debt issuance costs of $ 199,000 in additional paid-in capital for the three and six months ended June 30, 2022. Please refer to section "Repurchase of the Convertible Senior Notes – 2019". Further details of the Notes are as follows: Issuance Maturity Date Interest Rate First Interest Payment Date Effective Interest Rate Semi-Annual Interest Payment Dates Initial Conversion Rate per $1,000 Principal Initial Conversion Price Number of Shares (in millions) (1) 2019 Notes December 15, 2026 2 % June 15, 2020 2.47 % June 15; December 15 28.9415 $ 34.55 N/A 2021 Notes May 15, 2027 1.125 % May 15, 2022 1.72 % May 15; November 15 9.0061 $ 111.04 2.6 (1) The 2019 Notes were repurchased in November 2021 ($ 76.4 million) and June 2022 ($ 9.85 million). The Notes are senior unsecured obligations, do not contain any financial covenants and are governed by indentures for both (the Indentures). The total net proceeds from the Notes, after deducting initial debt issuance costs, fees and expenses, were $ 83.5 million and $ 278.4 million, respectively. We used a portion of the proceeds from the 2019 Notes to pay the cost of the capped call transactions described in the section “ Capped Calls ” and to repay our senior credit facility. We used approximately $ 183.6 million of the net proceeds of the 2021 Notes, excluding accrued intere st, to repurchase approximately $ 76.4 million aggregate principal amount of the 2019 Notes through individual privately negotiated transactions concurrent with us offering the 2021 Notes. We used approximately $ 17.6 million, excluding accrued interest, to repurchase the remaining $ 9.85 million aggregate principal amount of the 2019 Notes in June 2022. Please refer to the section “ Repurchase of the Convertible Senior Notes - 2019 ” for further details of both transactions. We will use the remainder of the net proceeds from the 2021 Notes for general corporate purposes. Terms of the Notes The Notes holders may convert their respective Notes at their option at any time prior to the close of business on the business day immediately preceding the respective conversion dates under the following circumstances: • during any fiscal quarter commencing after the fiscal quarter ended on March 31, 2022 for the 2021 Notes (and only during such fiscal quarter), if the last reported sale price of our common stock, for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding fiscal quarter is greater than or equal to 130 % of the conversion price on each applicable trading day; • during the five business day period after any five consecutive trading day period in which the trading price per $1,000 principal amount of the Notes for each trading day was less than 98 % of the product of the last reported sale price of our common stock and the conversion rate on each such trading day; • prior to the close of business on the second scheduled trading day immediately preceding the redemption date if we call the Notes for redemption; or • upon the occurrence of specified corporate events, as described in the indenture. Regardless of the foregoing circumstances, holders may convert all or any portion of the Notes, in increments of $1,000 principal amount, on or after February 15, 2027 (2021 Notes), until the close of business on the second scheduled trading day immediately preceding the maturity date. We may redeem all, or a portion of the Notes for cash, at our option, on or after November 20, 2024 (2021 Notes), if the last reported sale price of our common stock has been at least 130 % of the conversion price at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period at a redemption price equal to 100% of the principal amount of the Notes being redeemed, plus any accrued and unpaid interest to, but excluding, the redemption date. Notes holders who convert their Notes in connection with certain corporate events that constitute a make-whole fundamental change (as defined in the Indenture) are, under certain circumstances, entitled to an increase in the conversion rate. Additionally in the event of a corporate event constituting a fundamental change (as defined in the Indenture), Notes holders may require us to repurchase all or a portion of their Notes at a repurchase price equal to 100 % of the principal amount of the Notes being repurchased, plus any accrued and unpaid interest to, but excluding, the repurchase date. Accounting for the Notes Prior to January 1, 2021, we separated the 2019 Notes into liability and equity components. We determined the fair value of the liability component to be $ 52.5 million calculated as the present value of future cash flows discounted at the borrowing rate for a similar nonconvertible debt instrument based on the expected term. We determined the borrowing rate to be 9.90 % based on the market rates for nonconvertible debt instruments issued by other companies with publicly available credit ratings considered to be comparable to us. We recognized the excess of the principal amount of the 2019 Notes over the initial carrying amount of the liability component as a debt discount of $ 33.8 million and amortized it to interest expense over the expected term of the 2019 Notes using the effective interest rate method. We recorded the equity component of $ 33.8 million as additional paid-in capital, calculated as the difference between the total proceeds of $ 86.3 million and the initial carrying amount of the liability component. We allocated the 2019 Notes total issuance costs of $ 2.8 million between liability and equity in the same proportion as the allocation of our total proceeds to liability and equity components. We amortized the issuance costs attributable to the liability component of $ 1.7 million to interest expense over the respective term of the 2019 Notes using the effective interest rate method. We netted the issuance costs attributable to the equity component of $ 1.1 million against the respective equity component in additional paid-in capital. Effective January 1, 2021, we early adopted ASU 2020-06 using the modified retrospective approach. As a result, we accounted for the 2019 Notes as a single liability measured at amortized cost, as no other embedded features require bifurcation and recognition as derivatives. Upon adoption, we recorded a $ 29.3 million increase to long-term debt, a $ 32.7 million decrease to additional paid-in capital and a $ 3.4 million decrease to accumulated deficit. We had no changes to net deferred tax liabilities with a decrease in deferred tax liability offset by a corresponding increase in valuation allowance upon adoption. We accounted for the 2021 Notes issuance as a single liability measured at its amortized cost, as no other embedded features require bifurcation and recognition as derivatives. We presented the 2021 Notes total issuance costs of $ 9.1 million as a direct deduction from the face amount of the 2021 Notes. We amortized the issuance costs to interest expense over the respective term of the 2021 Notes using the effective interest rate method. Interest expense related to the Notes was as follows (in thousands): Three Months Ended September 30, 2022 Three Months Ended September 30, 2021 2019 Notes 2021 Notes Total 2019 Notes Total Amortization of debt issuance costs — 396 396 95 95 Cash interest expense — 809 809 431 431 Total interest expense $ — $ 1,205 $ 1,205 $ 526 $ 526 Nine Months Ended September 30, 2022 Nine Months Ended September 30, 2021 2019 Notes 2021 Notes Total 2019 Notes Total Amortization of debt issuance costs 19 1,184 1,203 282 282 Cash interest expense 87 2,426 2,513 1,294 1,294 Total interest expense $ 106 $ 3,610 $ 3,716 $ 1,576 $ 1,576 Accrued interest related to the 2021 Notes as of September 30, 2022 was $ 1.2 million. Accrued interest related to the 2019 Notes as of September 30, 2021 was $ 508,000 . We record accrued interest in accrued liabilities in our consolidated balance sheet. Our estimated fair value of the 2021 Notes was $ 288.6 million and $ 314.3 million as of September 30, 2022 and December 31, 2021, respectively, which we determined through consideration of quoted market prices. Our estimated fair value of the 2019 Notes was $ 26.2 million as of December 31, 2021, which we determined through consideration of quoted market prices. The fair value for the Notes is classified as Level 2, as defined in Note 2. Capped Calls In connection with issuing the 2019 Notes, we entered into privately negotiated capped-call transactions with certain financial counterparties. The capped-call transactions remain outstanding as of September 30, 2022, even though the 2019 Notes were repurchased in November 2021 and June 2022 as detailed below. The capped-call transactions are generally designed to reduce the potential dilution to our common stock upon any conversion or settlement of convertible debt, or to offset any cash payments we are required to make in excess of the principal amount upon conversion of convertible debt, as the case may be, with such reduction or offset subject to a cap based on the cap price. If, however, the market price per share of our common stock exceeds the cap price of the capped-call transactions, then our stock would experience some dilution and/or the capped call would not fully offset the potential cash payments, in each case, to the extent the then-market price per share of our common stock exceeds the cap price. The initial cap price of the capped-call transactions is $ 54.20 per share, which represents a 100 % premium over the last reported sale price of our common stock of $ 27.10 per share on December 11, 2019 subject to certain adjustments under the terms of the capped-call transactions. The capped-call transactions expire over 40 consecutive scheduled trading days ending on December 11, 2026 . The capped-call transactions meet the criteria for classification in equity, are not accounted for as derivatives, and are not remeasured each reporting period. We paid $ 10.1 million for the capped-call transactions , which we recorded as a reduction to additional paid-in-capital within shareholders’ equity. Repurchase of the Convertible Senior Notes – 2019 In November 2021 and June 2022, we completed a privately negotiated induced conversion of $ 76.4 million and $ 9.85 million principal amount, respectively of the 2019 Notes. We accounted for the 2019 Notes Repurchase transactions as induced conversions in accordance with Accounting Standards Codification 470-20, Debt with Conversion and Other Options (ASC 470-20). In connection with the induced conversions, we paid approximately $ 183.6 million in cash in November 2021 and $ 17.6 million in cash in June 2022, and also paid accrued and unpaid interest thereon. As a result of the induced conversion, we recorded $ 11.3 million in November 2021 and $ 2.2 million in June 2022 in induced conversion expense which is included in the Condensed Consolidated Statements of Operations. The induced conversion expense represents the fair value of the consideration issued upon conversion in excess of the fair value of the securities issuable under the original terms of the 2019 Notes. We accounted for the remaining cash consideration under the original terms of the 2019 Notes under the general conversion accounting guidance, where the difference between the carrying amount of the 2019 Notes retired, including unamortized debt issuance costs of $ 1.8 million in November 2021 and $ 199,000 in June 2022, and the cash consideration paid, was recorded in additional paid-in capital.

Leases

Leases	9 Months Ended
	Sep. 30, 2022
Leases [Abstract]
Leases	Note 7. Leases The following table presents the components of lease expense in our condensed consolidated statements of operations for the periods presented (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Operating lease costs (a) Single lease costs $ 1,078 $ 1,038 $ 3,164 $ 3,114 Variable lease costs 521 469 1,614 1,436 Sublease income (b) ( 494 ) ( 475 ) ( 1,482 ) ( 1,425 ) Total operating lease costs $ 1,105 $ 1,032 $ 3,296 $ 3,125 (a) Includes short-term lease costs, which are immaterial. (b) Sublease income is related to unused office space that we sublet as part of the restructuring in fiscal 2018 where we continue to have the primary obligations. The following table presents supplemental cash-flow information related to operating leases for the periods presented (in thousands): Nine Months Ended September 30, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows used $ 3,792 $ 3,668 Lease liabilities arising from remeasurement of right-of-use assets Operating leases $ — $ 698 Lease liabilities arising from obtaining ROU assets Operating leases $ 2,237 $ — The following table presents weighted-average remaining lease term and weighted-average discount rate related to operating leases as of the dates presented: September 30, 2022 December 31, 2021 Weighted-average remaining lease term (years) 4.4 4.4 Weighted-average discount rate 6.8 % 6.7 % The following table presents future lease payments under operating leases as of September 30, 2022 (in thousands): Operating Leases Lease Payments Sublease Income Net 2022 $ 1,308 $ ( 370 ) $ 938 2023 4,059 ( 123 ) 3,936 2024 3,853 — 3,853 2025 3,918 — 3,918 2026 4,019 — 4,019 Thereafter 1,815 — 1,815 Total lease payments $ 18,972 $ ( 493 ) $ 18,479 Less: Imputed interest ( 3,722 ) Present value of lease liabilities 15,250 Less: Current portion of lease liabilities 3,460 Lease liabilities, net of current portion $ 11,790

Net Loss Per Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Net Loss Per Share	Note 8. Net Loss Per Share Upon us adopting ASU 2020-06 using the modified retrospective transition method on January 1, 2021, we applied the “if-converted” method for calculating any potential dilutive effect of the conversion of the 2019 Notes or the 2021 Notes on diluted net loss per share for the three and nine months ended September 30, 2022 and September 30, 2021. The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss per share for the periods presented (in thousands, except per share amounts): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Numerator: Net loss $ ( 2,199 ) $ ( 12,924 ) $ ( 24,183 ) $ ( 31,246 ) Denominator: Weighted-average shares outstanding — basic and diluted 25,743 24,330 25,384 24,040 Net loss per share — basic and diluted $ ( 0.09 ) $ ( 0.53 ) $ ( 0.95 ) $ ( 1.30 ) The following table presents the outstanding shares of our common stock equivalents excluded from the computation of diluted net loss per share as of the dates presented because their effect would have been antidilutive (in thousands): Three and Nine Months Ended September 30, 2022 2021 Stock options 1,844 2,561 RSUs, MSUs, and PSUs 1,578 1,538 Employee stock purchase plan shares 30 42 2019 Notes — 2,496 2021 Notes 2,589 —

Segment Information

Segment Information	9 Months Ended
	Sep. 30, 2022
Segment Reporting [Abstract]
Segment Information	Note 9. Segment Information We have one reportable operating segment, which is the development and sale of our RAIN RFID products and services. We identify this one reportable segment based on how our chief operating decision-maker manages our business, makes decisions and evaluates our operating performance. Our chief executive officer is the chief operating decision-maker and reviews financial and operational information on an entity-wide basis as one business activity. We do not have segment managers who are separately accountable for operations, operating results or plans. Accordingly, we determined that we have a single reportable operating segment. The chief executive officer reviews information about our revenue categories, which are endpoint ICs and systems. We define systems as reader ICs, readers, gateways and software. The following table presents our revenue categories for the periods presented (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Endpoint ICs $ 51,155 $ 31,960 $ 132,804 $ 100,826 Systems 17,115 13,233 48,406 36,883 Total revenue $ 68,270 $ 45,193 $ 181,210 $ 137,709

Deferred Revenue

Deferred Revenue	9 Months Ended
	Sep. 30, 2022
Deferred Revenue Disclosure [Abstract]
Deferred Revenue	N ote 10. Deferred Revenue Deferred revenue, comprising individually immaterial amounts for extended warranty, enhanced maintenance and advance payments on non-recurring engineering services contracts, represents contracted revenue that has not yet been recognized. Deferred revenue as of December 31, 2020, included a $ 6.0 million advance payment for a system order, which we recognized as revenue for the nine months ended September 30, 2021. We recognized $ 319,000 of revenue related to amounts included in deferred revenue as of December 31, 2021 for the nine months ended September 30, 2022. The following table presents the changes in deferred revenue for the periods presented (in thousands): Nine Months Ended September 30, 2022 2021 Balance at beginning of period $ 794 $ 7,088 Deferral of revenue 3,058 956 Recognition of deferred revenue ( 700 ) ( 7,062 ) Balance at end of period $ 3,152 $ 982

Related-Party Transactions

Related-Party Transactions	9 Months Ended
	Sep. 30, 2022
Related Party Transactions [Abstract]
Related-Party Transactions	Note 11. Related-Party Transactions We have a consulting agreement with a limited liability company owned by Cathal Phelan, a member of our board of directors, pursuant to which Mr. Phelan provides advisory and consulting services. The term of the consulting agreement began in May 2020 through December 2020, which was extended by an additional 12 months to December 2021 as mutually agreed upon by Mr. Phelan and us. In 2021, again as mutually agreed by Mr. Phelan and us, we further extended the term by 12 months to December 2022. We recognized $ 115,000 and $ 385,000 of c onsulting fee expense to Mr. Phelan, or the limited liability company owned by Mr. Phelan, for the three and six months ended September 30, 2022 , respectively. We recognized $ 135,000 and $ 384,000 of consulting fee expense to Mr. Phelan, or the limited liability company owned by Mr. Phelan, for the three and nine months ended September 30, 2021, respectively.

Restructuring

Restructuring	9 Months Ended
	Sep. 30, 2022
Restructuring and Related Activities [Abstract]
Restructuring	Note 12. Restructuring On February 2, 2021, we restructured our go-to-market organization to strategically align our global sales, product, partner development and marketing teams. As part of the restructuring, we eliminated approximately seven full-time positions within our go-to-market organization, representing about 2 % of our workforce. We incurred restructuring charges of $ 1.7 million for employee termination benefits as well as $ 50,000 in other associated costs for legal expenses for the year ended December 31, 2021. We substantially completed our restructuring by June 30, 2021 . A summary of accrued restructuring costs as of September 30, 2022, is shown in the table below (in thousands): Employee Termination Benefits Other Associated Costs Total Restructuring costs incurred in 2021 $ 1,671 $ 50 $ 1,721 Cash payments in 2021 ( 1,080 ) ( 50 ) ( 1,130 ) Cash payments in 2022 ( 489 ) — ( 489 ) Accrued restructuring costs as of September 30, 2022 $ 102 $ — $ 102

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements include Impinj, Inc. and its wholly owned subsidiaries. We have eliminated intercompany balances and transactions in consolidation. We have prepared these condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles, or GAAP, and applicable rules and regulations of the Securities and Exchange Commission, or SEC, regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes as of and for the year ended December 31, 2021 included in Impinj, Inc.’s Annual Report on Form 10-K, which was filed with the SEC on February 14, 2022. The condensed consolidated balance sheet as of December 31, 2021, included herein, was derived from the audited consolidated financial statements of Impinj, Inc. The unaudited condensed consolidated interim financial statements, in the opinion of management, reflect all adjustments, consisting of normal recurring adjustments, necessary to state fairly our financial position, results of operations, and our cash flows for the periods presented. Interim results are not necessarily indicative of the results for a full year or for any other future period.
Use of Estimates	Use of Estimates Preparing financial statements in conformity with GAAP requires us to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures as of the date of the financial statements, as well as the reported amounts of revenue and expenses during the periods presented. On an ongoing basis, we evaluate our estimates, including those related to revenue recognition, sales incentives, estimates to complete development contracts, deferred revenue, inventory excess and obsolescence, income taxes, determination of the fair value of stock awards and compensation and employee-related benefits. To the extent there are material differences between these estimates, judgments, or assumptions and actual results, our financial statements will be affected.
Recently Adopted Accounting Standards	Recently Adopted Accounting Standards In August 2020, the FASB issued guidance on debt with conversion and other options, or ASU 2020-06. This guidance eliminates the beneficial- and cash-conversion accounting models for convertible instruments and amends the derivative scope exception for contracts in an entity’s own equity. Additionally, this guidance requires the application of the “if-converted” method to calculate the impact of convertible instruments on diluted earnings per share. We adopted ASU 2020-06 on January 1, 2021 using the modified retrospective transition method and accounted for the 2019 Notes (as defined below) on a whole-instrument basis. Upon adoption , we recorded a $ 29.3 million increase to long-term debt, a $ 32.7 million decrease to additional paid-in capital and a $ 3.4 million decrease to accumulated deficit on January 1, 2021. We had no changes to net deferred tax liabilities with a decrease in deferred tax liability offset by a corresponding increase in valuation allowance upon adoption. We use the “if-converted” method to calculate the impact of convertible instruments on diluted earnings per share for the three and nine months ended September 30, 2022 and 2021, upon adoption of this guidance. The condensed consolidated financial statements as of and for the three and nine months ended September 30, 2022, and 2021, are presented under ASU 2020-06.
Recently Issued Accounting Standards Not Yet Adopted	Recently Issued Accounting Standards Not Yet Adopted Recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the SEC did not have, or are not expected to have, a material impact on our present or future consolidated financial statements.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Summary of Assets Measured at Fair Value on Recurring Basis	The following table presents the balances of assets measured at fair value on a recurring basis, by level within the fair value hierarchy, as of the dates presented (in thousands): September 30, 2022 December 31, 2021 Level 1 Level 2 Total Level 1 Level 2 Total Cash equivalents: Money market funds $ 27,430 $ — $ 27,430 $ 113,058 $ — $ 113,058 Total cash equivalents 27,430 — 27,430 113,058 — 113,058 Short-term investments: U.S. government agency securities — 75,681 75,681 — 4,066 4,066 Corporate notes and bonds — 35,995 35,995 — 36,966 36,966 Commercial paper — 18,291 18,291 — 16,489 16,489 Treasury bill — 4,490 4,490 — 4,490 4,490 Yankee bonds 1,918 1,918 — — — Asset-backed securities — 6,166 6,166 — 7,432 7,432 Total short-term investments — 142,541 142,541 — 69,443 69,443 Long-term investments: U.S. government agency securities — 17,346 17,346 — 14,225 14,225 Asset-backed securities — 1,854 1,854 — — — Total long-term investments — 19,200 19,200 — 14,225 14,225 Total $ 27,430 $ 161,741 $ 189,171 $ 113,058 $ 83,668 $ 196,726
Schedule of Cost Or Amortized Cost, Gross Unrealized Gains, Gross Unrealized Losses, And Total Estimated Fair Value Of Financial Assets	The following tables present the cost or amortized cost, gross unrealized gains, gross unrealized losses and total estimated fair value of our financial assets as of the dates presented (in thousands): September 30, 2022 Cost or Gross Gross Total Estimated Amortized Cost Unrealized Gains Unrealized Losses Fair Value Description: Money market funds $ 27,430 $ — $ — $ 27,430 U.S. government agency securities 94,276 — ( 1,249 ) 93,027 Corporate notes and bonds 36,374 — ( 379 ) 35,995 Yankee bonds 1,920 — ( 2 ) 1,918 Commercial paper 18,291 — — 18,291 Treasury bill 4,500 — ( 10 ) 4,490 Asset-backed securities 8,110 — ( 90 ) 8,020 Total $ 190,901 $ — $ ( 1,730 ) $ 189,171 December 31, 2021 Cost or Gross Gross Total Estimated Amortized Cost Unrealized Gains Unrealized Losses Fair Value Description: Money market funds $ 113,058 $ — $ — $ 113,058 U.S. government agency securities 18,314 — ( 23 ) 18,291 Corporate notes and bonds 36,975 3 ( 12 ) 36,966 Commercial paper 16,489 — — 16,489 Treasury bill 4,494 — ( 4 ) 4,490 Asset-backed securities 7,435 — ( 3 ) 7,432 Total $ 196,765 $ 3 $ ( 42 ) $ 196,726

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Sep. 30, 2022
Inventory Disclosure [Abstract]
Schedule of Inventories	The following table presents the detail of inventories as of the dates presented (in thousands): September 30, 2022 December 31, 2021 Raw materials $ 10,982 $ 6,305 Work-in-process 9,178 7,873 Finished goods 11,765 7,780 Total inventory $ 31,925 $ 21,958

Stock-Based Awards (Tables)

Stock-Based Awards (Tables)	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Summary of Stock Options Activity	The following table summarizes stock option activity for the nine months ended September 30, 2022 (in thousands): Number of Outstanding at December 31, 2021 2,288 Granted — Exercised ( 426 ) Forfeited or expired ( 18 ) Outstanding at September 30, 2022 1,844 Vested and exercisable at September 30, 2022 1,517
Summary of Restricted Stock Units	The following table summarizes activity for RSUs, PSUs and MSUs for the nine months ended September 30, 2022 (in thousands): Number of Underlying Shares RSUs MSUs PSUs Outstanding at December 31, 2021 1,165 84 268 Granted 701 57 75 Vested ( 380 ) — ( 269 ) Forfeited ( 96 ) ( 25 ) ( 2 ) Outstanding at September 30, 2022 1,390 116 72
Summary of Stock-Based Compensation Expense	The following table presents stock-based compensation expense included in our condensed consolidated statements of operations for the periods presented (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Cost of revenue $ 509 $ 506 $ 1,407 $ 1,266 Research and development expense 4,368 4,610 13,479 12,288 Sales and marketing expense 1,853 2,617 7,247 6,739 General and administrative expense 3,327 3,187 10,097 8,658 Total stock-based compensation expense $ 10,057 $ 10,920 $ 32,230 $ 28,951

Long-term Debt (Tables)

Long-term Debt (Tables)	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Summary of Outstanding Principal Amount and Carrying Value	The following table presents the outstanding principal amount and carrying value of the Notes as of the dates indicated (in thousands): September 30, 2022 December 31, 2021 Principal Amount Unamortized debt issuance costs Net Carrying Amount Principal Amount Unamortized debt issuance costs Net Carrying Amount 2019 Notes (1) (2) $ — $ — $ — $ 9,850 $ ( 217 ) $ 9,633 2021 Notes 287,500 ( 7,654 ) 279,846 287,500 ( 8,839 ) 278,661 Total Debt 287,500 ( 7,654 ) 279,846 297,350 ( 9,056 ) 288,294 Short-term Debt — — — 9,850 ( 217 ) 9,633 Long-term Debt $ 287,500 $ ( 7,654 ) $ 279,846 $ 287,500 $ ( 8,839 ) $ 278,661 (1) In November 2021, we completed a privately negotiated repurchase of $ 76.4 million principal amount of the 2019 Notes (“2019 Note Repurchase”) which we accounted for as an induced conversion in accordance with Accounting Standards Codification 470-20, Debt with Conversion and Other Options (ASC 470-20). As a result of this transaction, we recorded unamortized debt issuance costs of $ 1.8 million in additional paid-in capital for the year ended December 31, 2021. Please refer to section "Repurchase of the Convertible Senior Notes – 2019". 9.85 million of the remaining principal amount of the 2019 Notes (“2019 Note Repurchase”) which we accounted for as an induced conversion in accordance with Accounting Standards Codification 470-20, Debt with Conversion and Other Options (ASC 470-20). As a result of this transaction, we recorded unamortized debt issuance costs of $ 199,000 in additional paid-in capital for the three and six months ended June 30, 2022. Please refer to section "Repurchase of the Convertible Senior Notes – 2019".
Schedule of Notes	Further details of the Notes are as follows: Issuance Maturity Date Interest Rate First Interest Payment Date Effective Interest Rate Semi-Annual Interest Payment Dates Initial Conversion Rate per $1,000 Principal Initial Conversion Price Number of Shares (in millions) (1) 2019 Notes December 15, 2026 2 % June 15, 2020 2.47 % June 15; December 15 28.9415 $ 34.55 N/A 2021 Notes May 15, 2027 1.125 % May 15, 2022 1.72 % May 15; November 15 9.0061 $ 111.04 2.6 (1) The 2019 Notes were repurchased in November 2021 ($ 76.4 million) and June 2022 ($ 9.85 million).
Schedule of Interest Expense	Interest expense related to the Notes was as follows (in thousands): Three Months Ended September 30, 2022 Three Months Ended September 30, 2021 2019 Notes 2021 Notes Total 2019 Notes Total Amortization of debt issuance costs — 396 396 95 95 Cash interest expense — 809 809 431 431 Total interest expense $ — $ 1,205 $ 1,205 $ 526 $ 526 Nine Months Ended September 30, 2022 Nine Months Ended September 30, 2021 2019 Notes 2021 Notes Total 2019 Notes Total Amortization of debt issuance costs 19 1,184 1,203 282 282 Cash interest expense 87 2,426 2,513 1,294 1,294 Total interest expense $ 106 $ 3,610 $ 3,716 $ 1,576 $ 1,576

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2022
Leases [Abstract]
Components of Lease Expense	The following table presents the components of lease expense in our condensed consolidated statements of operations for the periods presented (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Operating lease costs (a) Single lease costs $ 1,078 $ 1,038 $ 3,164 $ 3,114 Variable lease costs 521 469 1,614 1,436 Sublease income (b) ( 494 ) ( 475 ) ( 1,482 ) ( 1,425 ) Total operating lease costs $ 1,105 $ 1,032 $ 3,296 $ 3,125 (a) Includes short-term lease costs, which are immaterial. (b) Sublease income is related to unused office space that we sublet as part of the restructuring in fiscal 2018 where we continue to have the primary obligations.
Supplemental Cash Flow Information Related to Operating Leases	The following table presents supplemental cash-flow information related to operating leases for the periods presented (in thousands): Nine Months Ended September 30, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows used $ 3,792 $ 3,668 Lease liabilities arising from remeasurement of right-of-use assets Operating leases $ — $ 698 Lease liabilities arising from obtaining ROU assets Operating leases $ 2,237 $ —
Schedule of Weighted-Average Remaining Lease Terms and Weighted-Average Discount Rate Related to Operating Leases	The following table presents weighted-average remaining lease term and weighted-average discount rate related to operating leases as of the dates presented: September 30, 2022 December 31, 2021 Weighted-average remaining lease term (years) 4.4 4.4 Weighted-average discount rate 6.8 % 6.7 %
Schedule of Future Lease Payments under Operating Leases	The following table presents future lease payments under operating leases as of September 30, 2022 (in thousands): Operating Leases Lease Payments Sublease Income Net 2022 $ 1,308 $ ( 370 ) $ 938 2023 4,059 ( 123 ) 3,936 2024 3,853 — 3,853 2025 3,918 — 3,918 2026 4,019 — 4,019 Thereafter 1,815 — 1,815 Total lease payments $ 18,972 $ ( 493 ) $ 18,479 Less: Imputed interest ( 3,722 ) Present value of lease liabilities 15,250 Less: Current portion of lease liabilities 3,460 Lease liabilities, net of current portion $ 11,790

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Reconciliation of the Numerator and Denominator used in Computing Basic and Diluted Net Loss Per Share	The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss per share for the periods presented (in thousands, except per share amounts): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Numerator: Net loss $ ( 2,199 ) $ ( 12,924 ) $ ( 24,183 ) $ ( 31,246 ) Denominator: Weighted-average shares outstanding — basic and diluted 25,743 24,330 25,384 24,040 Net loss per share — basic and diluted $ ( 0.09 ) $ ( 0.53 ) $ ( 0.95 ) $ ( 1.30 )
Computation of Diluted Net Loss Per Share Effect in Antidilutive	The following table presents the outstanding shares of our common stock equivalents excluded from the computation of diluted net loss per share as of the dates presented because their effect would have been antidilutive (in thousands): Three and Nine Months Ended September 30, 2022 2021 Stock options 1,844 2,561 RSUs, MSUs, and PSUs 1,578 1,538 Employee stock purchase plan shares 30 42 2019 Notes — 2,496 2021 Notes 2,589 —

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Sep. 30, 2022
Segment Reporting [Abstract]
Summary of Revenue Categories	The following table presents our revenue categories for the periods presented (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Endpoint ICs $ 51,155 $ 31,960 $ 132,804 $ 100,826 Systems 17,115 13,233 48,406 36,883 Total revenue $ 68,270 $ 45,193 $ 181,210 $ 137,709

Deferred Revenue (Tables)

Deferred Revenue (Tables)	9 Months Ended
	Sep. 30, 2022
Deferred Revenue Disclosure [Abstract]
Summary of Changes in Deferred Revenue	The following table presents the changes in deferred revenue for the periods presented (in thousands): Nine Months Ended September 30, 2022 2021 Balance at beginning of period $ 794 $ 7,088 Deferral of revenue 3,058 956 Recognition of deferred revenue ( 700 ) ( 7,062 ) Balance at end of period $ 3,152 $ 982

Restructuring (Tables)

Restructuring (Tables)	9 Months Ended
	Sep. 30, 2022
Restructuring and Related Activities [Abstract]
Summary of Accrued Restructuring Costs	A summary of accrued restructuring costs as of September 30, 2022, is shown in the table below (in thousands): Employee Termination Benefits Other Associated Costs Total Restructuring costs incurred in 2021 $ 1,671 $ 50 $ 1,721 Cash payments in 2021 ( 1,080 ) ( 50 ) ( 1,130 ) Cash payments in 2022 ( 489 ) — ( 489 ) Accrued restructuring costs as of September 30, 2022 $ 102 $ — $ 102

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021	Jan. 01, 2021
Significant Accounting Policies [Line Items]
Long-term debt	$ 279,846	$ 278,661
Additional paid in capital	(390,432)	(351,422)
Accumulated deficit	$ 386,667	$ 362,484
ASU 2020-06
Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted	true
Change in accounting principle, accounting standards update, adoption date	Jan. 01, 2021
Change in accounting principle, accounting standards update, immaterial effect	false
ASU 2020-06 | Change in Accounting Method Accounted for as Change in Estimate | Revision of Prior Period, Accounting Standards Update, Adjustment
Significant Accounting Policies [Line Items]
Long-term debt			$ 29,300
Additional paid in capital			32,700
Accumulated deficit			$ 3,400

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Assets Measured at Fair Value on Recurring Basis (Details) - Fair Value Measurements Recurring - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	$ 189,171	$ 196,726
Cash Equivalents
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	27,430	113,058
Cash Equivalents | Money Market Funds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	27,430	113,058
Short-term Investments
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	142,541	69,443
Short-term Investments | U.S. Government Agency Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	75,681	4,066
Short-term Investments | Corporate Notes and Bonds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	35,995	36,966
Short-term Investments | Commercial Paper
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	18,291	16,489
Short-term Investments | Treasury Bill
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	4,490	4,490
Short-term Investments | Yankee Bonds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	1,918
Short-term Investments | Asset-backed Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	6,166	7,432
Long-term Investments
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	19,200	14,225
Long-term Investments | U.S. Government Agency Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	17,346	14,225
Long-term Investments | Asset-backed Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	1,854
Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	27,430	113,058
Level 1 | Cash Equivalents
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	27,430	113,058
Level 1 | Cash Equivalents | Money Market Funds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	27,430	113,058
Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	161,741	83,668
Level 2 | Short-term Investments
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	142,541	69,443
Level 2 | Short-term Investments | U.S. Government Agency Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	75,681	4,066
Level 2 | Short-term Investments | Corporate Notes and Bonds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	35,995	36,966
Level 2 | Short-term Investments | Commercial Paper
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	18,291	16,489
Level 2 | Short-term Investments | Treasury Bill
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	4,490	4,490
Level 2 | Short-term Investments | Yankee Bonds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	1,918
Level 2 | Short-term Investments | Asset-backed Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	6,166	7,432
Level 2 | Long-term Investments
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	19,200	14,225
Level 2 | Long-term Investments | U.S. Government Agency Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	17,346	$ 14,225
Level 2 | Long-term Investments | Asset-backed Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	$ 1,854

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities continuous loss position for less than 12 months, estimated fair value	$ 143,500,000	$ 61,000,000
Marketable securities continuous loss position for less than 12 months, unrealized losses	1,700,000	42,000
Marketable securities continuous loss position for greater than 12 months, estimated fair value	0	0
Marketable securities continuous loss position for greater than 12 months, unrealized losses	0	0
Fair Value Measurements Recurring
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	189,171,000	196,726,000
Liabilities measured at fair value	0	0
Fair Value Measurements Recurring | Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	$ 0	$ 0

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Cost Or Amortized Cost, Gross Unrealized Gains, Gross Unrealized Losses, And Total Estimated Fair Value Of Financial Assets (Details) - Fair Value Measurements Recurring - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cost or Amortized Cost	$ 190,901	$ 196,765
Gross Unrealized Gains		3
Gross Unrealized Losses	(1,730)	(42)
Total Estimated Fair Value	189,171	196,726
Money Market Funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cost or Amortized Cost	27,430	113,058
Gross Unrealized Gains
Gross Unrealized Losses
Total Estimated Fair Value	27,430	113,058
U.S. Government Agency Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cost or Amortized Cost	94,276	18,314
Gross Unrealized Gains
Gross Unrealized Losses	(1,249)	(23)
Total Estimated Fair Value	93,027	18,291
Corporate Notes and Bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cost or Amortized Cost	36,374	36,975
Gross Unrealized Gains		3
Gross Unrealized Losses	(379)	(12)
Total Estimated Fair Value	35,995	36,966
Yankee Bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cost or Amortized Cost	1,920
Gross Unrealized Gains
Gross Unrealized Losses	(2)
Total Estimated Fair Value	1,918
Commercial Paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cost or Amortized Cost	18,291	16,489
Gross Unrealized Gains
Gross Unrealized Losses
Total Estimated Fair Value	18,291	16,489
Treasury Bill
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cost or Amortized Cost	4,500	4,494
Gross Unrealized Gains
Gross Unrealized Losses	(10)	(4)
Total Estimated Fair Value	4,490	4,490
Asset-Backed Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cost or Amortized Cost	8,110	7,435
Gross Unrealized Gains
Gross Unrealized Losses	(90)	(3)
Total Estimated Fair Value	$ 8,020	$ 7,432

Inventory - Schedule of Invento

Inventory - Schedule of Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Raw materials	$ 10,982	$ 6,305
Work-in-process	9,178	7,873
Finished goods	11,765	7,780
Total inventory	$ 31,925	$ 21,958

Inventory - Additional Informat

Inventory - Additional Information (Details)	3 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2021
Inventory Disclosure [Abstract]
Inventory excess and obsolescence charges, favorable impact on gross margin percentage	2%	1.40%

Stock-Based Awards - Summary of

Stock-Based Awards - Summary of Stock Options Activity (Details) shares in Thousands	9 Months Ended
	Sep. 30, 2022 shares
Share-Based Payment Arrangement [Abstract]
Number of Underlying Shares, Outstanding, Beginning balance	2,288
Number of Underlying Shares, Exercised	(426)
Number of Underlying Shares, Forfeited or expired	(18)
Number of Underlying Shares, Outstanding, Ending balance	1,844
Number of Underlying Shares, Vested and exercisable	1,517

Stock-Based Awards - Additional

Stock-Based Awards - Additional Information (Details) - USD ($)		1 Months Ended	3 Months Ended		9 Months Ended
	Mar. 23, 2022	May 20, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense			$ 10,057,000	$ 10,920,000	$ 32,230,000	$ 28,951,000
MSU
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total shares granted	57,000	83,750			57,000
Estimated aggregate grant-date fair value	$ 4,600,000	$ 6,400,000
Stock based compensation expense			$ 262,000	$ 716,000	$ 2,200,000	$ 1,300,000

Stock-Based Awards - Summary _2

Stock-Based Awards - Summary of Restricted Stock Units (Details) - shares		1 Months Ended	9 Months Ended
	Mar. 23, 2022	May 20, 2021	Sep. 30, 2022
Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Underlying Shares Outstanding, Balance			1,165,000
Number of Underlying Shares, Granted			701,000
Number of Underlying Shares, Vested			(380,000)
Number of Underlying Shares, Forfeited			(96,000)
Number of Underlying Shares Outstanding, Balance			1,390,000
Market and Service Conditions Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Underlying Shares Outstanding, Balance			84,000
Number of Underlying Shares, Granted	57,000	83,750	57,000
Number of Underlying Shares, Forfeited			(25,000)
Number of Underlying Shares Outstanding, Balance			116,000
Performance Share Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Underlying Shares Outstanding, Balance			268,000
Number of Underlying Shares, Granted			75,000
Number of Underlying Shares, Vested			(269,000)
Number of Underlying Shares, Forfeited			(2,000)
Number of Underlying Shares Outstanding, Balance			72,000

Stock-Based Awards - Summary _3

Stock-Based Awards - Summary of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 10,057	$ 10,920	$ 32,230	$ 28,951
Cost of Revenue
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	509	506	1,407	1,266
Research and Development Expense
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	4,368	4,610	13,479	12,288
Selling and Marketing Expense
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	1,853	2,617	7,247	6,739
General and Administrative Expense
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 3,327	$ 3,187	$ 10,097	$ 8,658

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details)													1 Months Ended	2 Months Ended
	Oct. 20, 2022 Patent	Jul. 08, 2022 Patent	Feb. 10, 2022 Patent Trial	Sep. 03, 2021 Patent	Jul. 26, 2021 Patent	May 25, 2021 Patent	Dec. 11, 2020 Patent	Dec. 07, 2020 Patent	Oct. 27, 2020 Patent	Sep. 24, 2020 Patent	Oct. 04, 2019 Patent	Jun. 06, 2019 Patent	Feb. 29, 2020 Patent	Sep. 30, 2020 Patent	Sep. 30, 2022 USD ($)	Dec. 31, 2021 USD ($)	Mar. 09, 2021 Patent	Feb. 12, 2021 Patent
Commitments And Contingencies [Line Items]
Inventory purchase commitment, amount | $															$ 47,100,000
Number of infringement patents					1
Patent Infringement Claims
Commitments And Contingencies [Line Items]
Number of patents allegedly infringed								3			8	26
Number of patents, complaint filed												8
Number of patents found												6
Number of patents filed inter parties review with patent trail and appeal board							6						12
Number patents currently at issue													6
Number patents declined institute review														4
Amended complaint to remove without prejudice for number patents									2
Number of patents leaving in suit	3								4
Stay lifted for number of patents				2						2
Number of asserted patents						7		3			4
Number of asserted patents Invalid								3			8
Number of patents in suit pending final resolution of petitions							8
Number of patents on for IPRs																		2
Number of patents denied for IPRs																		4
Stay removed on number of patents																		4
Number of non-Infringement patents																	4
Number of infringement patents					9	9
Number of infringement patents exclusively licensed					8
Number of patents involved in initial trial			3
Number of additional trials for patents | Trial			2
Number of patents for reexamination petitions filed			5
Number of patent instituted re-examination of remaining six patent		1
Accrued Liabilities
Commitments And Contingencies [Line Items]
Contingent liabilities | $															$ 0	$ 0

Long-term Debt - Summary of Out

Long-term Debt - Summary of Outstanding Principal Amount and Carrying Value (Details) - USD ($)	Sep. 30, 2022	Jun. 30, 2022	Dec. 31, 2021	Nov. 30, 2021
Debt Instrument [Line Items]
Principal Amount	$ 287,500,000		$ 297,350,000
Unamortized debt issuance costs	(7,654,000)		(9,056,000)
Net Carrying Amount	279,846,000		288,294,000
Short-term Debt
Debt Instrument [Line Items]
Principal Amount			9,850,000
Unamortized debt issuance costs			(217,000)
Net Carrying Amount			9,633,000
Long-term Debt
Debt Instrument [Line Items]
Principal Amount	287,500,000		287,500,000
Unamortized debt issuance costs	(7,654,000)		(8,839,000)
Net Carrying Amount	279,846,000		278,661,000
2019 Convertible Senior Notes due 2026
Debt Instrument [Line Items]
Principal Amount			9,850,000
Unamortized debt issuance costs		$ (199,000)	(217,000)	$ (1,800,000)
Net Carrying Amount			9,633,000
2021 Convertible Senior Notes due 2027
Debt Instrument [Line Items]
Principal Amount	287,500,000		287,500,000
Unamortized debt issuance costs	(7,654,000)		(8,839,000)
Net Carrying Amount	$ 279,846,000		$ 278,661,000

Long-term Debt - Summary of O_2

Long-term Debt - Summary of Outstanding Principal Amount and Carrying Value (Parenthetical) (Details) - USD ($)	1 Months Ended		9 Months Ended
	Jun. 30, 2022	Nov. 30, 2021	Sep. 30, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Unamortized debt issuance costs			$ 7,654,000	$ 9,056,000
2019 Convertible Senior Notes due 2026
Debt Instrument [Line Items]
Repurchase of debt principal amount		$ 76,400,000	$ 9,850,000
Unamortized debt issuance costs	$ 199,000	1,800,000		217,000
2019 Note Repurchase | 2019 Convertible Senior Notes due 2026
Debt Instrument [Line Items]
Repurchase of debt principal amount	9,850,000	$ 76,400,000
Unamortized debt issuance costs	$ 199,000			$ 1,800,000

Long-term Debt - Convertible Se

Long-term Debt - Convertible Senior Notes - Additional Information (Details)		1 Months Ended			9 Months Ended
	Dec. 11, 2019 $ / shares	Jun. 30, 2022 USD ($)	Nov. 30, 2021 USD ($)	Dec. 31, 2019 USD ($) d $ / shares	Sep. 30, 2022 USD ($) d	Dec. 31, 2021 USD ($)	Sep. 30, 2021 USD ($)	Jan. 01, 2021 USD ($)
Debt Instrument [Line Items]
Debt instrument, threshold trading days | d					5
Number of business day | d					5
Long-term debt					$ 279,846,000	$ 278,661,000
Additional paid in capital					(390,432,000)	(351,422,000)
Accumulated deficit					386,667,000	362,484,000
Payment for capped call transactions				$ 10,100,000
Induced conversion expense related to convertible notes					2,232,000
Unamortized debt issuance costs					7,654,000	9,056,000
ASU 2020-06 | Change in Accounting Method Accounted for as Change in Estimate | Revision of Prior Period, Accounting Standards Update, Adjustment
Debt Instrument [Line Items]
Long-term debt								$ 29,300,000
Additional paid in capital								32,700,000
Accumulated deficit								$ 3,400,000
2019 Convertible Senior Notes due 2026
Debt Instrument [Line Items]
Debt instrument, maturity date				Dec. 15, 2026
Net proceeds from issuing notes				$ 83,500,000
Repurchase of debt principal amount			$ 76,400,000		9,850,000
Debt instrument, borrowing interest rate percentage				9.90%
Fair value of liability component upon issuance				$ 52,500,000
Initial carrying amount of liability component recognized as debt discount				33,800,000
Proceeds from convertible debt				86,300,000
Adjustments recorded in additional paid-in capital				33,800,000
Total issuance costs				2,800,000
Liability issuance costs				1,700,000
Equity issuance costs				$ 1,100,000
Accrued interest							$ 508,000
Cap price of the capped call transactions | $ / shares				$ 54.20
Premium percentage on sale price of common stock	100%
Common stock sale price per share last reported | $ / shares	$ 27.10
Capped call transactions expiration consecutive days | d				40
Capped call transaction expiring date	Dec. 11, 2026
Payment of 2019 Notes			183,600,000		17,600,000
Induced conversion expense related to convertible notes		$ 2,200,000	11,300,000
Unamortized debt issuance costs		199,000	1,800,000			217,000
2019 Convertible Senior Notes due 2026 | Level 2
Debt Instrument [Line Items]
Estimated fair value						26,200,000
2019 Convertible Senior Notes due 2026 | 2019 Note Repurchase
Debt Instrument [Line Items]
Payment of 2019 Notes		17,600,000	183,600,000
Repurchase of debt principal amount		9,850,000	$ 76,400,000
Unamortized debt issuance costs		$ 199,000				1,800,000
2019 Convertible Promissory Notes due 2026
Debt Instrument [Line Items]
Aggregate principal amount				$ 86,300,000
Debt instrument, maturity date				Dec. 15, 2026
2021 Convertible Senior Notes due 2027
Debt Instrument [Line Items]
Debt instrument, maturity date			May 15, 2027
Net proceeds from issuing notes			$ 278,400,000
Total issuance costs			9,100,000
Accrued interest					1,200,000
Unamortized debt issuance costs					7,654,000	8,839,000
2021 Convertible Senior Notes due 2027 | Level 2
Debt Instrument [Line Items]
Estimated fair value					$ 288,600,000	$ 314,300,000
2021 Convertible Promissory Notes due 2027
Debt Instrument [Line Items]
Aggregate principal amount			$ 287,500,000
Debt instrument, maturity date			May 15, 2027
Convertible Senior Notes
Debt Instrument [Line Items]
Debt instrument, threshold consecutive trading days | d					30
Debt instrument, threshold percentage of stock price trigger					130%
Debt instrument, terms of conversion feature					Regardless of the foregoing circumstances, holders may convert all or any portion of the Notes, in increments of $1,000 principal amount, on or after February 15, 2027 (2021 Notes), until the close of business on the second scheduled trading day immediately preceding the maturity date.
Percentage of repurchase price of principal amount					100%
Convertible Senior Notes | Minimum
Debt Instrument [Line Items]
Debt instrument, threshold trading days | d					20
Convertible Senior Notes | Maximum
Debt Instrument [Line Items]
Debt instrument, threshold percentage of stock price trigger					98%

Long-term Debt - Schedule of No

Long-term Debt - Schedule of Notes (Details) Unit in Millions	1 Months Ended
	Nov. 30, 2021 Unit $ / shares shares	Dec. 31, 2019 $ / shares shares
2019 Notes
Debt Instrument [Line Items]
Maturity Date		Dec. 15, 2026
Interest Rate		2%
First Interest Payment Date		Jun. 15, 2020
Effective Interest Rate		2.47%
Semi-Annual Interest Payment Dates		June 15; December 15
Initial Conversion Rate per $1,000 Principal | shares		28.9415
Initial Conversion Price | $ / shares		$ 34.55
2021 Notes
Debt Instrument [Line Items]
Maturity Date	May 15, 2027
Interest Rate	1.125%
First Interest Payment Date	May 15, 2022
Effective Interest Rate	1.72%
Semi-Annual Interest Payment Dates	May 15; November 15
Initial Conversion Rate per $1,000 Principal | shares	9.0061
Initial Conversion Price | $ / shares	$ 111.04
Number of Shares (in millions) | Unit	2.6

Long-term Debt - Schedule of _2

Long-term Debt - Schedule of Notes (Parenthetical) (Details) - 2019 Convertible Senior Notes due 2026 - USD ($) $ in Thousands	1 Months Ended		9 Months Ended
	Jun. 30, 2022	Nov. 30, 2021	Sep. 30, 2022
Debt Instrument [Line Items]
Repurchase of debt principal amount		$ 76,400	$ 9,850
2019 Note Repurchase
Debt Instrument [Line Items]
Repurchase of debt principal amount	$ 9,850	$ 76,400

Long-term Debt - Schedule of In

Long-term Debt - Schedule of Interest Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
2019 Convertible Senior Notes due 2026
Debt Instrument [Line Items]
Amortization of debt issuance costs		$ 95	$ 19	$ 282
Cash interest expense		431	87	1,294
Total interest expense		526	106	1,576
2021 Convertible Senior Notes due 2027
Debt Instrument [Line Items]
Amortization of debt issuance costs	$ 396		1,184
Cash interest expense	809		2,426
Total interest expense	1,205		3,610
Convertible Senior Notes
Debt Instrument [Line Items]
Amortization of debt issuance costs	396	95	1,203	282
Cash interest expense	809	431	2,513	1,294
Total interest expense	$ 1,205	$ 526	$ 3,716	$ 1,576

Leases - Components of Lease Ex

Leases - Components of Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Operating lease costs
Single lease costs	$ 1,078	$ 1,038	$ 3,164	$ 3,114
Variable lease costs	521	469	1,614	1,436
Sublease income:
Sublease income	(494)	(475)	(1,482)	(1,425)
Total operating lease costs	$ 1,105	$ 1,032	$ 3,296	$ 3,125

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow Information Related to Operating Leases (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows used	$ 3,792	$ 3,668
Lease liabilities arising from remeasurement of right-of-use assets
Operating leases		$ 698
Lease liabilities arising from obtaining ROU assets
Operating leases	$ 2,237

Leases - Schedule of Weighted-A

Leases - Schedule of Weighted-Average Remaining Lease Terms and Weighted-Average Discount Rate Related to Operating Leases (Details)	Sep. 30, 2022	Dec. 31, 2021
Leases [Abstract]
Weighted-average remaining lease term (years)	4 years 4 months 24 days	4 years 4 months 24 days
Weighted-average discount rate	6.80%	6.70%

Leases - Schedule of Future Lea

Leases - Schedule of Future Lease Payments under Operating Leases (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Leases [Abstract]
Operating Leases, Lease Payments, 2022	$ 1,308
Operating Leases, Lease Payments, 2023	4,059
Operating Leases, Lease Payments, 2024	3,853
Operating Leases, Lease Payments, 2025	3,918
Operating Leases, Lease Payments, 2026	4,019
Operating Leases, Lease Payments, Thereafter	1,815
Operating Leases, Lease Payments, Total lease payments	18,972
Less: Imputed interest	(3,722)
Present value of lease liabilities	15,250
Current portion of operating lease liabilities	3,460	$ 4,143
Operating lease liabilities, net of current portion	11,790	$ 11,934
Operating Leases, Sublease Income, 2022	(370)
Operating Leases, Sublease Income, 2023	(123)
Operating Leases, Sublease Income, Total lease payments	(493)
Operating Leases, Net, 2022	938
Operating Leases, Net, 2023	3,936
Operating Leases, Net, 2024	3,853
Operating Leases, Net, 2025	3,918
Operating Leases, Net, 2026	4,019
Operating Leases, Net, Thereafter	1,815
Operating Leases, Net, Total lease payments	$ 18,479

Net Loss Per Share - Reconcilia

Net Loss Per Share - Reconciliation of the Numerator and Denominator used in Computing Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021
Numerator:
Net loss	$ (2,199)	$ (11,523)	$ (10,461)	$ (12,924)	$ (8,906)	$ (9,416)	$ (24,183)	$ (31,246)
Denominator:
Weighted-average shares outstanding - basic	25,743			24,330			25,384	24,040
Weighted-average shares outstanding - diluted	25,743			24,330			25,384	24,040
Net loss per share - basic	$ (0.09)			$ (0.53)			$ (0.95)	$ (1.30)
Net loss per share - diluted	$ (0.09)			$ (0.53)			$ (0.95)	$ (1.30)

Net Loss Per Share - Computatio

Net Loss Per Share - Computation of Diluted Net Loss Per Share Effect in Antidilutive (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Stock Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	1,844	2,561	1,844	2,561
RSUs, MSUs, and PSUs
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	1,578	1,538	1,578	1,538
Employee Stock Purchase Plan Shares
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	30	42	30	42
2019 Notes
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share		2,496		2,496
2021 Notes
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	2,589		2,589

Segment Information - Additiona

Segment Information - Additional Information (Details)	9 Months Ended
	Sep. 30, 2022 Segment
Segment Reporting [Abstract]
Number of reportable operating segment	1

Segment Information - Summary o

Segment Information - Summary of Revenue Categories (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Segment Reporting Information [Line Items]
Total revenue	$ 68,270	$ 45,193	$ 181,210	$ 137,709
Endpoint ICs
Segment Reporting Information [Line Items]
Total revenue	51,155	31,960	132,804	100,826
Systems
Segment Reporting Information [Line Items]
Total revenue	$ 17,115	$ 13,233	$ 48,406	$ 36,883

Deferred Revenue - Additional I

Deferred Revenue - Additional Information (Details) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Deferred Revenue Disclosure [Abstract]
Remaining performance obligation		$ 6,000,000
Recognition of deferred revenue	$ 319,000

Deferred Revenue - Summary of C

Deferred Revenue - Summary of Changes in Deferred Revenue (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Deferred Revenue Disclosure [Abstract]
Balance at beginning of period	$ 794	$ 7,088
Deferral of revenue	3,058	956
Recognition of deferred revenue	(700)	(7,062)
Balance at end of period	$ 3,152	$ 982

Related-Party Transactions - Ad

Related-Party Transactions - Additional Information (Details) - Cathal Phelan - Advisory and Consulting Services - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Related Party Transaction [Line Items]
Consulting agreement extended term			12 months
Consulting fee expense recognized and paid	$ 115,000	$ 135,000	$ 385,000	$ 384,000

Restructuring - Additional Info

Restructuring - Additional Information (Details)	1 Months Ended	9 Months Ended	12 Months Ended
	Feb. 02, 2021 Position	Sep. 30, 2022	Dec. 31, 2021 USD ($)
Restructuring Cost and Reserve [Line Items]
Restructuring and related activities, description		On February 2, 2021, we restructured our go-to-market organization to strategically align our global sales, product, partner development and marketing teams. As part of the restructuring, we eliminated approximately seven full-time positions within our go-to-market organization, representing about 2% of our workforce. We incurred restructuring charges of $1.7 million for employee termination benefits as well as $50,000 in other associated costs for legal expenses for the year ended December 31, 2021. We substantially completed our restructuring by June 30, 2021
Number of positions eliminated | Position	7
Number of positions eliminated, percent	2%
Restructuring charges			$ 1,721,000
Restructuring and related activities, completion date	Jun. 30, 2021
Employee Termination Benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges			1,671,000
Other Associated Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges			$ 50,000

Restructuring - Summary of Accr

Restructuring - Summary of Accrued Restructuring Costs (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Restructuring Cost and Reserve [Line Items]
Restructuring charges		$ 1,721,000
Cash payments	$ (489,000)	(1,130,000)
Accrued restructuring costs as of September 30, 2022	102,000	591,000
Employee Termination Benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges		1,671,000
Cash payments	(489,000)	(1,080,000)
Accrued restructuring costs as of September 30, 2022	$ 102,000
Other Associated Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges		50,000
Cash payments		$ (50,000)